findmyKOL

Mark Litzow, MD

Enriched profile

Professor of Medicine, Division of Hematology, Mayo Clinic (Rochester, MN); Head of the Acute Leukemia and Myeloid Neoplasm Group · Mayo Clinic

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Rochester, MN · Midwest · United StatesSpecialtyHematologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2001–2003

Mark Litzow is Professor of Medicine, Division of Hematology, Mayo Clinic (Rochester, MN); Head of the Acute Leukemia and Myeloid Neoplasm Group at Mayo Clinic. OpenAlex indexes 1,323 publications with 48,382 citations (h-index 106); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Mark Litzow, M.D., is Professor of Medicine, Division of Hematology, Mayo Clinic (Rochester, MN). The public record shows 1,323 publications with 48,382 citations (h-index 106), centered on Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 9 companies, 1 NIH-funded awards (2001–2003).

  • Most recent indexed publication: 2026 · Blood advances
  • Top research focus: Acute Myeloid Leukemia Research
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)6 trialsLeukemia, Myeloid, Acute2 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialPhiladelphia Chromosome1 trialLeukemia, Erythroblastic, Acute1 trialOvarian / Gynecologic Cancer1 trialMDS / MPN

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsHematopoietic Stem Cell TransplantationMyeloproliferative Neoplasms: Diagnosis and Treatment

Drugs & molecules

across trials, industry payments and publications
Blincytogeneric · BlinatumomabClinical trials1Industry payments18Publications7Rylazegeneric · AsparaginaseClinical trials1Industry payments1Publications3CytarabineClinical trials4Industry payments—Publications3MethotrexateClinical trials2Industry payments—Publications3DaunorubicinClinical trials3Industry payments—Publications1RituximabClinical trials1Industry payments—Publications3FludarabineClinical trials1Industry payments—Publications2ImatinibClinical trials1Industry payments—Publications2PrednisoneClinical trials2Industry payments—Publications1AlvocidibClinical trials1Industry payments—Publications1MitoxantroneClinical trials1Industry payments—Publications1CyclophosphamideClinical trials4Industry payments—Publications—

Works with

trial sponsors and companies reporting payments
Amgen Inc.Clinical trials—Industry payments20AstraZeneca Pharmaceuticals LPClinical trials—Industry payments4Eastern Cooperative Oncology GroupClinical trials4Industry payments—Mayo ClinicClinical trials3Industry payments—Kite Pharma, Inc.Clinical trials—Industry payments2National Cancer Institute (NCI)Clinical trials2Industry payments—BeiGene (Suzhou) Co., Ltd.Clinical trials—Industry payments1E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments1Jazz Pharmaceuticals Inc.Clinical trials—Industry payments1Medexus Pharma, Inc.Clinical trials—Industry payments1National Marrow Donor ProgramClinical trials—Industry payments1Servier Pharmaceuticals LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,323publications

Distinct works indexed by OpenAlex, matched via ORCID; 156 in PubMed.

48,382citations

Total citations across indexed works.

106h-index

Hirsch index (OpenAlex). i10-index 507.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials ↓
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2001–2003

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

All 9 trial records: search, sort and filter.Explore →

Industry payments

Updated 14 Oct 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 13 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    25.9%
    Beta blocker13.5%
    Metoprolol Succinate54%Carvedilol46%
    Part D<11 patients
    Statin12.4%
    Rosuvastatin Calcium100%
    Part D<11 patients

  • Cancer & immunology

    23.8%
    Kinase inhibitor14%
    Jakafi56%Imatinib Mesylate44%
    Part D<11 patients
    Antimetabolite9.8%
    Hydroxyurea100%
    Part D<11 patients

  • Anti-infectives

    19.2%
    Penicillin-class Antibacterial19.2%
    Penicillin V Potassium100%
    Part D≥12 patients
All 7 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B), 202330.4% facility · 69.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

1 NIH research award on record, funded 2001–2003 per NIH RePORTER. The latest:

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 156 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
    1,948 citations2012
    doi.org ↗
  2. 02
    Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
    1,259 citations2014
    doi.org ↗
  3. 03
    MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
    1,040 citations2006
    doi.org ↗
  4. 04
    International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
    966 citations2015
    doi.org ↗
  5. 05
    Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
    953 citations2018
    doi.org ↗
All 1,323 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

William J. Hogan440Mrinal M. Patnaik334Aref Al‐Kali313Hassan B. Alkhateeb249Ayalew Tefferi236Naseema Gangat228Martin S. Tallman220Hillard M. Lazarus192Mithun Vinod Shah185Elisabeth Paietta183Selina M. Luger180James M. Foran174Kebede H. Begna167Abhishek A. Mangaonkar148Michelle A. Elliott135Animesh Pardanani129Rhett P. Ketterling112Angela Dispenzieri110Talha Badar109Morie A. Gertz107Shahrukh K. Hashmi106Martha Q. Lacy106Jacob M. Rowe102Wael Saber80Luis F. Porrata75Partow Kebriaei74Shaji Kumar73Hemant S. Murthy72David J. Inwards71Jacob M. Rowe70Mehrdad Hefazi67Daniel J. Weisdorf66Suzanne R. Hayman65David I. Marks65David S. Viswanatha65Harry P. Erba64Rong He64Patricia T. Greipp63Stephen M. Ansell62David Dingli61

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/mark-litzow-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/mark-litzow-7a844a15b

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • LinkedIn

    linkedin.com/in/mark-litzow-a9021319a

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Mark-Litzow-2173652157

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Mark-R-Litzow-39637735

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/p/DQxvHCmDIhy

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • Other

    vjhemonc.com/speaker/mark-litzow

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship

    Hematology and Medical Oncology, Mayo Clinic College of Medicine and Science (Rochester), 1986-1989 (NOTE: fresh-pass input listed this as "completed 1990" sourced to Healthgrades …

    1990
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • Internal Medicine Residency

    Mayo Clinic College of Medicine and Science (Rochester), 1980-1984

    1984
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • M.D.

    University of Chicago Division of the Biological Sciences, Pritzker School of Medicine

    1980
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • Board Certified

    American Board of Internal Medicine: Internal Medicine, Hematology, Medical Oncology, and Hospice and Palliative Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Editorial & leadership roles

journal and society appointments
  • Former Chair

    Leukemia Committee, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) -- chaired 2013-2022, succeeded by Selina M. Luger, MD as of December 2022 (PAST role …

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog-ecog-acrin.org ↗
  • Former Director

    Blood and Marrow Transplant (BMT) Program, Mayo Clinic (1992-2008); remains actively involved in the BMT program in an unspecified capacity (PAST directorship, ongoing informal involvement)

    2008
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bmtinfonet.org ↗
  • Head

    Acute Leukemia and Myeloid Neoplasm Group / Acute Leukemia Group, Division of Hematology, Mayo Clinic (current)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.elsevierpure.com ↗
  • Added as provisional past role rather than omitted

    since it appeared unprompted in an independent verification search.

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.